Immune Checkpoint Inhibitors and Pregnancy: Analysis of the VigiBase® Spontaneous Reporting System
Open Access
Abstract
In pregnancy, immune checkpoint pathways are involved in the maintenance of fetomaternal immune tolerance. Preclinical studies have shown that immune checkpoint inhibitors (ICIs) increase the risk of fetal death. Despite the fact that using ICIs in pregnant women and women of childbearing potential is not recommended, some case reports of ICI exposure in pregnancy have been published showing favorable fetal outcomes. This study aimed to gain further insight into ICI safety in pregnancy by querying VigiBase®, the World Health Organization’s spontaneous reporting system. We performed raw and subgroup disproportionality analyses using the reporting odds ratio and comparing ICIs with the entire database, other antineoplastic agents, and other antineoplastic agents gathered in VigiBase® since 2011. Across 103 safety reports referring to ICI exposure during the peri-pregnancy period, 56 reported pregnancy-related outcomes, of which 46 were without concomitant drugs as potential confounding factors. No signals of disproportionate reporting were found for spontaneous abortion, fetal growth restriction, and prematurity. In light of the expanding indications of ICIs, continuous surveillance by clinicians and pharmacovigilance experts is warranted, along with pharmacoepidemiological studies on other sources of real-world evidence, such as birth records, to precisely assess ICI exposure during the peri-pregnancy period and further characterize relevant outcomes.Keywords
This publication has 49 references indexed in Scilit:
- An Evaluation of the Impact of PD‐1 Pathway Blockade on Reproductive Safety of Therapeutic PD‐1 InhibitorsBirth Defects Research Part B: Developmental and Reproductive Toxicology, 2016
- Signal of Gastrointestinal Congenital Malformations with Antipsychotics After Minimising Competition Bias: A Disproportionality Analysis Using Data from Vigibase®Drug Safety, 2016
- Performance of Stratified and Subgrouped Disproportionality Analyses in Spontaneous DatabasesDrug Safety, 2016
- Prescription Opioids in Pregnancy and Birth Outcomes: A Review of the LiteratureJournal of Pediatric Genetics, 2015
- Cancer during pregnancy and the postpartum period: A population‐based studyCancer, 2015
- Recent Insight into the Role of the PD‐1/PD‐L1 Pathway in Feto‐Maternal Tolerance and PregnancyAmerican Journal of Reproductive Immunology, 2015
- The Link between the PDL1 Costimulatory Pathway and Th17 in Fetomaternal ToleranceThe Journal of Immunology, 2011
- An interspecies comparison of placental antibody transfer: New insights into developmental toxicity testing of monoclonal antibodiesBirth Defects Research Part B: Developmental and Reproductive Toxicology, 2009
- Pharmacological approaches to the management of pain in the neonatal intensive care unitJournal of Perinatology, 2007
- A critical role for the programmed death ligand 1 in fetomaternal toleranceJournal of Experimental Medicine, 2005